Incivek (telaprevir) is a protein pharmaceutical. Telaprevir was first approved as Incivek on 2011-05-23. It is used to treat chronic hepatitis c and hepatitis c in the USA. It is known to target lysosomal protective protein and chymotrypsin-like elastase family member 1. Incivo's patents are valid until 2028-05-30 (FDA).
|Indication||chronic hepatitis c, hepatitis c|
|Drug Class||Antivirals: serine protease inhibitors|